ESLA Estrella Immunopharma, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1844417 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY6.7%
TTM EPS YoY20.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-484.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets936.1%
Debt / equity—
Current ratio0.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-143.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $10.25M | $4.11M | $10.45M | — | — |
| SG&A expense | $2.81M | $3.20M | $663,190 | — | — |
| Operating income | -$13.06M | -$7.31M | -$11.11M | -$1.57M | -$249,146 |
| Pretax income | -$13.06M | -$7.31M | -$11.11M | -$915,456 | -$247,718 |
| Income tax | $838 | $1,625 | — | $80,648 | $0 |
| Net income | -$13.06M | -$7.31M | -$11.11M | -$996,104 | -$247,718 |
| EPS (basic) | -0.35 | -0.27 | -36.35 | — | — |
| EPS (diluted) | -0.35 | -0.27 | -36.35 | — | — |
| Weighted avg. shares (diluted) | 36.82M | 27.10M | 305,748 | — | 1.18M |
| Banking | |||||
| Deposits | $1.50M | $1.50M | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $1.38M | $4.17M | $2.48M | $2.88M | $478,868 |
| Receivables | — | — | $273,066 | — | — |
| Current assets | $1.68M | $4.45M | $2.75M | $52,427 | $616,034 |
| Total assets | $3.18M | $4.45M | $3.03M | $9.72M | $45.80M |
| Current liabilities | $13.54M | $180,701 | $9.76M | $1.07M | $73,154 |
| Total liabilities | $13.54M | $180,701 | $9.77M | $2.65M | $1.62M |
| Shareholders' equity | -$10.37M | $4.27M | -$11.74M | -$6.48M | -$1.01M |
| Shares outstanding | 37.97M | 36.61M | 978,243 | 1.42M | 1.42M |
| Cash flow statement | |||||
| Operating cash flow | -$1.79M | -$16.07M | -$1.34M | -$1.04M | -$316,158 |
| Investing cash flow | — | $4.96M | -$273,066 | $36.17M | -$45.19M |
| Financing cash flow | $2.25M | $12.79M | — | -$35.56M | $45.98M |
| Stock-based compensation | $618,974 | $1.19M | $409,595 | — | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.